Clinical Trial Update: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III trial compares HR070803 plus FOLFOX with bevacizumab versus FOLFOX with bevacizumab as first-line treatment for advanced colorectal cancer; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Calcium folinate (calcium folinate)
• HR070803
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Colorectal Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING